Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tert-butyl 4-({[4-(but-2-yn-1-ylamino)phenyl]sulfonyl}methyl)-4-[(hydroxyamino)carbonyl]piperidine-1-carboxylate
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is a synthetic small molecule belonging to the class of sulfonylanilines, featuring a piperidine core substituted with both a hydroxyaminocarbonyl group and a sulfonamide-linked butynylaniline moiety. It is listed as an experimental pharmaceutical in chemical databases and has been referenced in research contexts, but there are no indications of clinical use or advanced development. Its structure suggests potential utility as an inhibitor of matrix metalloproteinases (MMPs), particularly MMP13 (collagenase 3), MMP14, and MMP2, based on related chemical annotations. However, no detailed mechanism of action or therapeutic indication has been established in public sources[3][2][1].
- Other names
- TERT-BUTYL 4-({[4-(BUT-2-YN-1-YLAMINO)PHENYL]SULFONYL}METHYL)-4-[(HYDROXYAMINO)CARBONYL]PIPERIDINE-1-CARBOXYLATEtert-butyl 4-{[4-(but–2–yn–1–ylamino)benzenesulfonyl]methyl}-4-(hydroxycarbamoyl)piperidine–1-carboxylatetert-butyl 4-[({4-[but–2–yn–1–ylamino]benzene}sulfonyl)methyl]-4-(hydroxycarbamoyl)piperidine–1-carboxylate
02
Targets
MMP13 (Matrix metalloproteinase-13)MMP14 (Matrix metalloproteinase 14)MMP2 (Matrix metalloproteinase-2)
Beyond the preview
Go deeper on tert-butyl 4-({[4-(but-2-yn-1-ylamino)phenyl]sulfonyl}methyl)-4-[(hydroxyamino)carbonyl]piperidine-1-carboxylate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tert-butyl 4-({[4-(but-2-yn-1-ylamino)phenyl]sulfonyl}methyl)-4-[(hydroxyamino)carbonyl]piperidine-1-carboxylate.